{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:07:24Z","timestamp":1792076844149,"version":"4.4.0"},"reference-count":31,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI127893"],"award-info":[{"award-number":["R01AI127893"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI141707"],"award-info":[{"award-number":["R01AI141707"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","award":["DRG-2271-16"],"award-info":[{"award-number":["DRG-2271-16"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mahan Postdoctoral Fellowship","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Antivirals are used not only in the current treatment of influenza but are also stockpiled as a first line of defense against novel influenza strains for which vaccines have yet to be developed. Identifying drug resistance mutations can guide the clinical deployment of the antiviral and can additionally define the mechanisms of drug action and drug resistance. Pimodivir is a first-in-class inhibitor of the polymerase basic protein 2 (PB2) subunit of the influenza A virus polymerase complex. A number of resistance mutations have previously been identified in treated patients or cell culture. Here, we generate a complete map of the effect of all single-amino-acid mutations to an avian PB2 on resistance to pimodivir. We identified both known and novel resistance mutations not only in the previously implicated cap-binding and mid-link domains, but also in the N-terminal domain. Our complete map of pimodivir resistance thus enables the evaluation of whether new viral strains contain mutations that will confer pimodivir resistance.<\/jats:p>","DOI":"10.3390\/v13071196","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T22:10:59Z","timestamp":1624399859000},"page":"1196","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comprehensive Profiling of Mutations to Influenza Virus PB2 That Confer Resistance to the Cap-Binding Inhibitor Pimodivir"],"prefix":"10.3390","volume":"13","author":[{"given":"Y. Q. Shirleen","family":"Soh","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Basic Sciences Division, Seattle, WA 98109, USA"},{"name":"Fred Hutchinson Cancer Research Center, Computational Biology Program, Seattle, WA 98109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keara D.","family":"Malone","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Basic Sciences Division, Seattle, WA 98109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel T.","family":"Eguia","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Basic Sciences Division, Seattle, WA 98109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1267-3408","authenticated-orcid":false,"given":"Jesse D.","family":"Bloom","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Basic Sciences Division, Seattle, WA 98109, USA"},{"name":"Fred Hutchinson Cancer Research Center, Computational Biology Program, Seattle, WA 98109, USA"},{"name":"Howard Hughes Medical Institute, Seattle, WA 98109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Nguyen-Van-Tam, J.S., and Bresee, J. (2013). Pandemic preparedness and response. Textbook of Influenza, John Wiley & Sons, Ltd.","DOI":"10.1002\/9781118636817.ch28"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ajic.2016.09.024","article-title":"Oseltamivir for pandemic influenza preparation: Maximizing the use of an existing stockpile","volume":"45","author":"Patel","year":"2017","journal-title":"Am. J. Infect. Control."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1586\/14787210.4.5.795","article-title":"Resistance to anti-influenza drugs: Adamantanes and neuraminidase inhibitors","volume":"4","author":"Hurt","year":"2006","journal-title":"Expert Rev. Anti-infective Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(05)67338-2","article-title":"Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern","volume":"366","author":"Bright","year":"2005","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/QCO.0000000000000498","article-title":"Neuraminidase inhibitor resistance in influenza: A clinical perspective","volume":"31","author":"Lee","year":"2018","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1126\/science.1187816","article-title":"Permissive Secondary Mutations Enable the Evolution of Influenza Oseltamivir Resistance","volume":"328","author":"Bloom","year":"2010","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"a038687","DOI":"10.1101\/cshperspect.a038687","article-title":"Influenza Polymerase Inhibitors: Mechanisms of Action and Resistance","volume":"11","author":"Takashita","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","article-title":"Influenza virus polymerase inhibitors in clinical development","volume":"32","author":"Hayden","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrmicro3367","article-title":"At the centre: Influenza A virus ribonucleoproteins","volume":"13","author":"Eisfeld","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrmicro.2016.87","article-title":"Influenza virus RNA polymerase: Insights into the mechanisms of viral RNA synthesis","volume":"14","author":"Fodor","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coviro.2019.01.006","article-title":"Baloxavir marboxil: The new influenza drug on the market","volume":"35","author":"Shaw","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a Novel, First-in-Class, Orally Bioavailable Azaindole Inhibitor (VX-787) of Influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1128\/AAC.04623-14","article-title":"Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit","volume":"59","author":"Byrn","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3851\/IMP3212","article-title":"Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: A Phase IIa, randomized, double-blind, placebo-controlled study","volume":"23","author":"Trevejo","year":"2018","journal-title":"Antivir. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/infdis\/jiy547","article-title":"Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial","volume":"219","author":"Finberg","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Gregor, J., Radilov\u00e1, K., Brynda, J., Fanfrl\u00edk, J., Konvalinka, J., and Ko\u017e\u00ed\u0161ek, M. (2021). Structural and Thermodynamic Analysis of the Resistance Development to Pimodivir (VX-787), the Clinical Inhibitor of Cap Binding to PB2 Subunit of Influenza A Polymerase. Molecules, 26.","DOI":"10.3390\/molecules26041007"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e02718-20","DOI":"10.1128\/AAC.02718-20","article-title":"Whole-Genome Analysis Surveillance of Influenza A Virus Resistance to Polymerase Complex Inhibitors in Eastern Spain from 2016 to 2019","volume":"65","author":"Cano","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to favipiravir in influenza","volume":"115","author":"Goldhill","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9385","DOI":"10.1038\/s41598-017-09538-x","article-title":"Structural basis for therapeutic inhibition of influenza A polymerase PB2 subunit","volume":"7","author":"Ma","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/nar\/gkx1210","article-title":"Capped RNA primer binding to influenza polymerase and implications for the mechanism of cap-binding inhibitors","volume":"46","author":"Pflug","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e45079","DOI":"10.7554\/eLife.45079","article-title":"Comprehensive mapping of adaptation of the avian influenza polymerase protein PB2 to humans","volume":"8","author":"Soh","year":"2019","journal-title":"eLife"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e00067-10","DOI":"10.1128\/mBio.00067-10","article-title":"The PB2-E627K Mutation Attenuates Viruses Containing the 2009 H1N1 Influenza Pandemic Polymerase","volume":"1","author":"Jagger","year":"2010","journal-title":"mBio"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1073\/pnas.100133697","article-title":"A DNA transfection system for generation of influenza A virus from eight plasmids","volume":"97","author":"Hoffmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Doud, M.B., and Bloom, J.D. (2016). Accurate measurement of the effects of all amino-acid mutations on influenza hemagglutinin. Viruses, 8.","DOI":"10.1101\/047571"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Doud, M.B., Hensley, S.E., and Bloom, J.D. (2017). Complete mapping of viral escape from neutralizing antibodies. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006271"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature15525","article-title":"Crystal structure of the RNA-dependent RNA polymerase from influenza C virus","volume":"527","author":"Hengrung","year":"2015","journal-title":"Nature"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/7\/1196\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:21:10Z","timestamp":1760163670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/7\/1196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["v13071196"],"URL":"https:\/\/doi.org\/10.3390\/v13071196","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.05.11.443605","asserted-by":"object"}]},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]}}}